A Randomized, Double-blind, Placebo-controlled Phase 3 Study to evaluate Dostarlimab as Sequential Therapy after Chemoradiation in Participants with Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

Sponsor:

GlaxoSmithKline

Sponsor Study ID:

221530 JADE

CTO #:

103960

NCT Number:

NCT06256588

Phase:

III

Protocol Type:

Treatment

Age Group:

Adults

Disease Sites:

Lip, Oral Cavity and Pharynx

Study Objectives:

To evaluate the efficacy of dostarlimab as sequential therapy following CRT as compared to placebo in participants with PD-L1 positive LA unresected HNSCC as per BICR. To estimate the difference in overall survival (OS) for participants treated with dostarlimab as sequential therapy following CRT as compared to placebo in participants with LA unresected HNSCC.

eConsent:

Not available

Study Documents:

Open Study Documents
(MUSC NetID required for document access)